Tagged with clinical

Malaysia Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir Mohamad returning as Prime Minister after 15 years to seal a historic victory, Malaysia is again back on its feet. Bolstered by well-established institutions, a fully-functional IP framework and strong…

Malaysia A map showing 18 of the active clinical trials sites in Malaysia in 2017. The sites are spread across the entire nation and cover a variety of therapeutic areas – including gastroenterology / hepatology, cardiology and oncology –  with a cluster of activity in Kuala Lumpur.   In terms of…

Malaysia Malaysia’s multi-ethnic population, disease burden, medical infrastructure and research speed, combined with its population’s proficiency in English, make the Southeast Asian nation a potentially excellent regional clinical trials destination.   We have a population of 32 million which represents a third of the world’s genomics Dr Akhmal Yusof, CRM Dr…

Malysia Dr Goh Pik Pin, director of the Clinical Research Centre (CRC), and Dr Salina Abd Aziz, consultant psychiatrist and chairperson, MOH Medical Research Ethics Committee, and head, CRC Hospital Kuala Lumpur, highlight the main improvements of the CRC as well as the clinical research environment in Malaysia since 2014. Dr…

Korea From Wednesday 31st October to Friday 2nd November, Seoul hosted the KoNECT-MFDS International conference, promoting South Korea’s clinical research capabilities on a global platform. The fourth of its kind, the conference was based around the main theme of embracing change in clinical research. The conference was organised by KoNECT –…

Malaysia Dr Akhmal Yusof, CEO of CRM sheds light on the capacity for all stages of clinical research in Malaysia. He discusses the importance of human resources for the country’s research future and explains what makes Malaysia such a worthwhile location to invest in international clinical research.   If we consider…

Algeria Radwa Terbeche, general manager of Amgen in Algeria discusses the potential for biosimilars in Algeria and the company’s role in developing a local clinical research infrastructure.   What has been your journey to becoming country manager of Amgen Algeria? By education I am a pharmacist specialized in industry. After graduating,…

Turkey Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to life-changing innovation. He also pinpoints MSD’s exceptional and enduring commitment to Turkey, which has led the company to emerge as…

Biogen After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field where research has met relentless challenges and a series of drug candidates have been unsuccessful. Indeed, the failure rate for Alzheimer’s drugs has been 99.6 percent over the…

Portugal Eurotrials is a full-service contract research organization (CRO) with an international footprint in over five territories worlwide. Following the trend of big pharma, Eurotrials recently merged with CTI, an American privately owned clinical trial and consulting service. Maria Queiroz founded the company in 1995 with Inês Costa, and here puts…

Europe The top spenders on pharma R&D in Europe for 2015 were Switzerland – which spent over EUR 6.5 billion – followed by Germany – which spent EUR 6.2 billion – and the UK – which spent EUR 5.8 billion.

Portugal Paulo Teixeira shines a light on Pfizer’s promising pipeline for 2018, the market access environment in Portugal and the clinical trial landscape. Teixeira intends to contribute to improving society’s perception of the pharmaceutical industry and position Pfizer as a partner for health and wellbeing in Portugal; part of the solution—not…